Beyond Tumor Mutation Burden: Tumor Neoantigen Burden as a Biomarker for Immunotherapy and Other Types of Therapy

Frontiers in Oncology

Yueyun Chen¹  Peipei Wang¹  Chun Wang² 

[1] Department of Biotherapy, Cancer Center, West China Hospital, State Key Laboratory of Biotherapy, Sichuan University, Chengdu, China;Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu, China;

关键词: tumor neoantigen burden;    biomarker;    immunotherapy;    immune response;    tumor mutation burden;   

DOI  :  10.3389/fonc.2021.672677

来源: DOAJ

【 摘 要 】

Immunotherapy has significantly improved the clinical outcome of patients with cancer. However, the immune response rate varies greatly, possibly due to lack of effective biomarkers that can be used to distinguish responders from non-responders. Recently, clinical studies have associated high tumor neoantigen burden (TNB) with improved outcomes in patients treated with immunotherapy. Therefore, TNB has emerged as a biomarker for immunotherapy and other types of therapy. In the present review, the potential application of TNB as a biomarker was evaluated. The methods of neoantigen prediction were summarized and the mechanisms involved in TNB were investigated. The impact of high TNB and increased number of infiltrating immune cells on the efficacy of immunotherapy was also addressed. Finally, the future challenges of TNB were discussed.

【 授权许可】

Unknown